New Strategies in the Treatment of Dyslipidemia: Do We Know How?

ABSTRACT

The treatment of dyslipidemia is beyond doubt one of the cornerstones of cardiovascular prevention. If we want to touch and comment on at least the principal news in this broad field, we must simplify and pay attention to only a few selected areas. The focus of this article is on hypercholesterolemia and the treatment options for elevated low-density lipoprotein (LDL)-cholesterol; it also addresses the questions of low high-density lipoprotein (HDL)-cholesterol levels and the treatment of dyslipidemia of the metabolic syndrome. In particular, statins have had accumulation of new evidence resulting in novel indications and new target groups. Modern, even more potent drugs lowering total and LDL-cholesterol levels are available (new statins, e.g., rosuvastatin, pitavastatin, cholesterol absorption inhibitor ezetimibe) More and more attention of the medical public is being paid to dyslipidemia of the metabolic syndrome (so-called lipid triad), which seems to be the greatest rival of LDL-cholesterol among lipid risk factors for cardiovascular disease. In the treatment of this dyslipidemia especially the nuclear peroxisome proliferator-activated receptor (PPAR) agonists play an important role. In particular fibrates but also glithasones are noteworthy in this respect. There are fewer data for fibrates than for statins, but nevertheless evidence documenting benefit of this therapy is growing. A statin and fibrate combination is a promising future approach not only to the treatment of metabolic syndrome. Moreover, niacin, particularly in combination with a statin, might experience a renaissance. HDL-cholesterol level modification attracts more and more discussions; on the horizon there are new therapies of low HDL, for example, cholesterol-ester transfer protein inhibitors, which have been shown to have a potency for increasing HDL by more than 50%.

KEYWORDS

LDL-cholesterol - metabolic syndrome - HDL-cholesterol - statins - ezetimibe - fibrates - niacin - intervention trial

REFERENCES

• 1 Kannel W B, Castelli W P, Gordon T, McNamara P M. Serum cholesterol, lipoproteins and risk of coronary heart disease. The Framingham Study.  Ann Intern Med. 1971;  74 1-12
• 2 Keys A. Coronary heart disease in seven countries.  Circulation. 1970;  41(suppl I) I1-I24
• 3 Stamler J, Wentworth D, Neaton J D. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).  JAMA. 1986;  256 2823-2828
• 4 The Lipid Research Clinics Program . The Lipid Research Clinics Coronary Primary Prevention Trial results: I. Reduction in incidence of coronary heart disease.  JAMA. 1984;  251 351-364
• 5 Frick M H, Elo  O, Haapa  K et al.. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle aged men with dyslipidemia.  N Engl J Med. 1987;  3l7 1237-1245
• 6 Scandinavian Simvastatin Survival Study Group . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S).  Lancet. 1994;  344 1383-1389
• 7 LIPID Study Group . Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average chlesterol concentrations: the LIPID trial follow-up.  Lancet. 2002;  359 1379-1387
• 8 Simes J, Furberg C D, Braunwald E et al.. Pravastatin reduces mortality in patients with and without CHD.  Eur Heart J. 2002;  23 207-215
• 9 Pedersen T R, Wilhelmsen L, Faergeman O et al.. Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering.  Am J Cardiol. 2000;  86 257-262
• 10 Mackness M I, Mackness B. HDL: are there any benefits from raising it?. In: Betteridge DJ Lipids and Vascular Disease, Current Issues London; Martin Dunitz 2000: 15-27
• 11 Austin M. Plasma triglyceride and coronary heart disease.  Arterioscler Thromb. 1991;  11 2-14
• 12 Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men.  Am J Cardiol. 1996;  77 1179-1184
• 13 Cífková R for the members of steering committee . Prevence ischemické choroby srdeční v dospělém věku.  Kapitoly Kardiol. 2000;  2 122-139
• 14 Heart Protection Study Collaborative Group . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial.  Lancet. 2002;  360 7-22
• 15 Athyros V G, Papageorgiu A A, Mercouris B R et al.. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus “usual” care in secondary coronary heart disease prevention. The Greek atorvastatin and coronary heart disease evaluation (GREACE) study.  Curr Med Res Opin. 2002;  18 220-228
• 16 Sever P S, Dahlof B, Poulter N R et al.. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.  Lancet. 2003;  361 1149-1158
• 17 The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group . Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care.  JAMA. 2002;  288 2998-3007
• 18 Nissen S E, Tuzcu E M, Schoenhagen P et al.. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomised controlled trial.  JAMA. 2004;  291 1071-1080
• 19 Serruys P WJC, deFeyter P, Macaya C et al.. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. A randomized controlled trial.  JAMA. 2002;  287 3215-3222
• 20 Cannon C P, Braunwald E, McCabe H C et al.. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.  N Engl J Med. 2004;  350 1495-1504
• 21 Robins S J, Collins D, Wittes J T et al.. Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomised controlled trial.  JAMA. 2001;  285 1585-1591
• 22 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).  JAMA. 2001;  285 2486-2497
• 23 Lauer M S, Fontanarosa P B. Updated guidelines for cholesterol management.  JAMA. 2001;  285 2508-2509
• 24 DeBacker G, Ambrosioni E, Borch-Johnsen K et al.. European guidelines on cardiovascular disease prevention in clinical practice.  Eur Heart J. 2003;  24 1601-1610
• 25 Schwartz G C, Olsson A G, Ezekowitz M D et al.. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study.  JAMA. 2001;  285 1711-1718
• 26 Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival.  JAMA. 2001;  285 430-436
• 27 Bellamy M F, Pellika P A, Klarich K W et al.. Association of cholesterol levels, HMG-CoA reductase inhibitor treatment, and progression of aortic stenosis in the community.  J Am Coll Cardiol. 2002;  40 1723-1730
• 28 Pearlman A S. Medical treatment of aortic stenosis.  J Am Coll Cardiol. 2002;  40 1731-1734
• 29 Shepherd J, Blauw G J, Murphy M B et al.. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.  Lancet. 2002;  360 1623-1630
• 30 Allen Maycock C A, Muhelstein J B, Horne B D et al.. Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients.  J Am Coll Cardiol. 2002;  40 1777-1785
• 31 DeJongh S, Lilien M R, Roodt J et al.. Early statin therapy restores endothelial function in children with familial hypercholesterolemia.  J Am Coll Cardiol. 2002;  40 2117-2121
• 32 Tsimikas S, Witzum J L. Shifting the diagnosis and treatment of atherosclerosis to children and young adults: a new paradigm for the 21st century.  J Am Coll Cardiol. 2002;  40 2122-2124
• 33 Law M R, Wald N J, Rudnicka A R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease and stroke: systematic review and meta-analysis.  BMJ. 2003;  326 1423
• 34 Sacks F M. Low-density lipoprotein lowering therapy: an analysis of the option.  J Am Coll Cardiol. 2002;  40 2135-2138
• 35 Jones P H, Davidson M H, Stein E A et al.. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR Trial).  Am J Cardiol. 2003;  93 152-160
• 36 Shepherd J. Combined lipid lowering drug therapy for the effective treatment of hypercholesterolemia.  Eur Heart J. 2003;  24 685-689
• 37 Davidson M H, McGarry T, Bettis R et al.. Ezetimibe co-administered with simvastatin in patients with primary hypercholesterolemia.  J Am Coll Cardiol. 2002;  40 2125-2134
• 38 Brousseau M E, Schaefer E J, Wolfe M L et al.. Effects of an inhibitor of cholesteryl-ester transfer protein in HDL cholesterol.  N Engl J Med. 2004;  350 1505-1515